Pds Biotechnology (PDSB)
NASDAQ:PDSB
Want to see PDSB full AI Analyst Report?
Earnings Data
Report Date
Aug 18, 2026TBA (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.13Last Year’s EPS
-0.21Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed meaningful clinical and intellectual property progress: a strategic protocol amendment for VERSATILE-003 that reduces patient count (~28.6%) and time to an interim readout, peer-reviewed and encouraging clinical data for PDS01ADC, strengthened IP extending PDS0101 protection into the 2040s, and established manufacturing processes. Financially, operating expenses and net loss improved year-over-year. Key risks include a relatively modest cash balance ($21.7M), continued unprofitability with rising interest expense, the need for OS data for full approval and additional confirmatory trials, and competition in the HPV16 head and neck space. On balance, the operational and clinical positives outweigh the near-term financial and development risks.Company Guidance
Protocol amendment for VERSATILE-003 to enable faster path to approval
Amended trial to add progression-free survival (PFS) as an interim co-primary endpoint while retaining overall survival (OS) for full approval; randomization changed from 2:1 to 1:1 and planned enrollment reduced from ~350 to ~250 patients (≈28.6% reduction), expected to shorten duration and lower trial costs and time to an interim readout.
Clinical momentum and site retention
Sites remained with the program through a pause and are preparing to restart enrollment following the FDA-aligned amendment, supporting continued recruitment momentum for VERSATILE-003.
PDS0101 program: unique product attributes and IP protection
PDS0101 is the only late-stage investigational HPV16-positive HNSCC therapy requiring five doses and administered subcutaneously; new U.S. and Japanese patents granted and anticipated biologics exclusivity extend market protection into the 2040s.
PDS01ADC: positive clinical data and peer-reviewed publication
Promising results reported for PDS01ADC in colorectal cancer (Stage 1 data published in JCO Oncology Advances) and encouraging early results in metastatic castration-resistant prostate cancer (NCI-led study); colorectal Stage 2 cohort fully enrolled with additional data expected by year-end.
Manufacturing and CMC readiness for Versamune
Commercial manufacturing process is established and scale-up has been performed; remaining work focuses on validation and CMC activities in parallel with Phase III to support a BLA filing, described as a straightforward path to commercialization.
Improved operating expense profile and smaller net loss
Net loss improved to $7.3M ($0.13 per share) in Q1 2026 from $8.5M ($0.21) in Q1 2025 (net loss decrease ≈14.1%; loss per share improved ≈38.1%); total operating expenses declined to $6.5M from $9.1M (≈28.6% reduction).
Lower R&D and G&A spend
R&D expense decreased to $3.5M from $5.8M (≈39.7% reduction) primarily due to lower clinical and manufacturing costs; G&A decreased modestly to $3.1M from $3.3M (≈6.1% reduction).
PDSB Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
PDSB Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 13, 2026 | $1.10 | $1.33 | +20.91% |
Mar 30, 2026 | $0.54 | $0.54 | -0.92% |
Nov 13, 2025 | $0.96 | $0.84 | -12.25% |
Aug 13, 2025 | $1.23 | $1.16 | -5.69% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Pds Biotechnology (PDSB) report earnings?
Pds Biotechnology (PDSB) is schdueled to report earning on Aug 18, 2026, TBA (Confirmed).
What is Pds Biotechnology (PDSB) earnings time?
Pds Biotechnology (PDSB) earnings time is at Aug 18, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PDSB EPS forecast?
PDSB EPS forecast for the fiscal quarter 2026 (Q2) is -0.13.